Aesthetic Medical International Holdings Group Limited

What they do

The company operates specialty outpatient facilities providing aesthetic medical services in China through subsidiaries including Shenzhen Pengai Xiuqi Aesthetic Medical Hospital Co., Ltd., Guangzhou Pengai Aesthetic Medical Hospital Co., Ltd., Shanghai Pengai Aesthetic Medical Outpatient Department Co., Ltd., Yantai Pengai Cosmetic Surgery Hospital Co., Ltd., and Beijing Aomei Yixin Investment Consultant Co., Ltd. and its Pengai Aesthetic Medical Clinic branch. It is registered in the Cayman Islands and its principal executive offices are at 1122 Nanshan Boulevard, Nanshan District, Shenzhen, Guangdong Province, China. It files as a foreign private issuer on Form 20-F.

Revenue drivers

• Aesthetic medical services — Revenue is generated by operating specialty outpatient aesthetic medical facilities and hospitals in China, including the Shenzhen Pengai Xiuqi, Guangzhou Pengai, Guangzhou Pengai Xiuqi, Shanghai Pengai, Shanghai Pengai Xiuqi, Yantai Pengai, and Beijing Aomei Yixin Pengai Aesthetic Medical Clinic entities. The filing excerpts do not disclose revenue by facility or service line.
• Hospital and clinic operations — The company operates a network of wholly or contractually controlled medical facilities in multiple Chinese cities. No revenue or margin contribution per city or facility is provided in the excerpts.
• Aesthetic medical services in China — All described operations are located in Mainland China, with service delivery through the Relevant Subsidiaries and the Beijing Aomei Yixin clinic branch. No international operations are disclosed in the excerpts.

Recent performance

The excerpts provided do not include income statement, balance sheet, or cash flow figures for the fiscal year ended December 31, 2025. The only year-end data point disclosed is that 147,326,504 ordinary shares were issued and outstanding as of December 31, 2025. No revenue, net income, same-facility growth, or segment results are available in the source material. Because the 20-F excerpt captured here is largely cover-page and table-of-contents text, no latest reported financial results can be cited.

Strategy

The excerpts describe a series of contractual arrangements entered into with Mr. Zhou Qiuming, Dr. Zhou Pengwu, Shenzhen Pengai Hospital Investment Management Co., Ltd., the Relevant Subsidiaries, Ms. Ma Xiuhua, and Ms. Ding Wenting from 2018 to 2025 with respect to the Target Equity Interests. The contractual arrangement structure is referenced as a continuing governance feature of the group. No specific capital expenditure, expansion, or new product plans are disclosed in the excerpts. The filing identifies the company as a non-accelerated filer or emerging growth company for SEC reporting purposes.

Risks

• Contractual arrangement enforceability — The company's control over the Relevant Subsidiaries depends on contractual arrangements with Mr. Zhou Qiuming, Dr. Zhou Pengwu, Shenzhen Pengai Hospital Investment Management Co., Ltd., Ms. Ma Xiuhua, and Ms. Ding Wenting rather than direct equity ownership.
• China regulatory exposure — Substantially all operations are in Mainland China, exposing the company to PRC laws and regulations governing medical facilities and foreign investment, which differ from those in the Cayman Islands or the United States.
• OTC Market trading and disclosure — The ADSs trade on the OTC Market under PAIYY rather than a national securities exchange, and the company files as a foreign private issuer on Form 20-F, which involves different disclosure and reporting requirements than U.S. domestic issuers.
• Limited information in source excerpt — The filing excerpt supplied for review contains predominantly cover-page and table-of-contents text with no financial statements, so operating performance and financial condition cannot be assessed from it.

Outlook

The excerpts do not include management's forward-looking outlook, guidance, or commentary on future periods. No expected revenue, earnings, capital spending, or facility expansion plans are stated in the source material. As a result, no outlook can be summarized beyond what is disclosed.